Dystrophin Immunity in Duchenne's Muscular Dystrophy
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
We report on delivery of a functional dystrophin transgene to skeletal muscle in six patients with Duchenne's muscular dystrophy. Dystrophin-specific T cells were detected after treatment, providing evidence of transgene expression even when the functional protein was not visualized in skeletal muscle. Circulating dystrophin-specific T cells were unexpectedly detected in two patients before vector treatment. Revertant dystrophin fibers, which expressed functional, truncated dystrophin from the deleted endogenous gene after spontaneous in-frame splicing, contained epitopes targeted by the autoreactive T cells. The potential for T-cell immunity to self and nonself dystrophin epitopes should be considered in designing and monitoring experimental therapies for this disease. (Funded by the Muscular Dystrophy Association and others; ClinicalTrials.gov number, NCT00428935.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the first mini-dystrophin clinical trial (NCT00428935), completed in 2010, most parsimoniously failed due to immune responses developed against the transgene, which was delivered in the biceps muscle using the AAV2.5 vector [122].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [122]
In the citing paper
“To date, transgene immune responses in AAV gene therapy have been mostly reported in muscle-directed clinical trials [94, 115–119].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [94]
In the citing paper
“Similarly, capsid-specific T-cell responses were limited or not observed in DMD clinical trials [94, 95].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [94]
In the citing paper
“Interestingly, pre-existing cellular immunity to dystrophin may occur in some patients with Duchene’s muscular dystrophy, a disease characterized by muscle regeneration and some level inflammation (55).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [55]
In the citing paper
“In clinical trials, CD8+ T cell responses have been observed against dystrophin and α1-antitrypsin in treatment of Duchenne’s muscular dystrophy and α1-antitrypsin (AAT) deficiency, respectively (55, 56).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [55]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673
Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Self-citation
Research works printed but not linked: 1
- Klein CJ, 1992, Am J Hum Genet, 50, 950
Cited by
Items 101–200 of 679
Stem cell therapies for muscle disorders
Tedesco, F. S., & Cossu, G. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328357f288 · Cited by 107
Gene therapy clinical trials worldwide to 2023—an update
Ginn, S. L., Mandwie, M., Alexander, I. E., Edelstein, M. L., & Abedi, M. R. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.3721 · Cited by 112
“52,53 The immense success shown using the AAV9 capsid in the treatment of infants with spinal muscular atrophy (SMA) highlights the potential of vectors based on AAV.”
The potential of adeno-associated viral vectors for gene delivery to muscle tissue
Wang, D., Zhong, L., Nahid, M. A., & Gao, G. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.871258 · Cited by 98
“Such a CD8 T-cell response has been observed in several clinical trials, including the liver-directed hemophilia trials [95,129], muscle-directed LPLD trial [130] and DMD trial [131].”
AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models
Sondergaard, P. C., Griffin, D. A., Pozsgai, E. R., Johnson, R. W., Grose, W. E., Heller, K. N., Shontz, K. M., Montgomery, C. L., Liu, J., Clark, K. R., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.172 · Cited by 99
Self-citationImmune Response Mechanisms against AAV Vectors in Animal Models
Martino, A. T., & Markusic, D. M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.008 · Cited by 97
“Adaptive CD8 T cell immune response against transgene product was identified in several Duchenne muscular dystrophy (DMD) patients treated with IM delivery of an AAV1 vector expressing the mini-dystrophin protein.(90) However, this response was not uniform among patients within the same dose cohort.”
BackgroundAnthony, K., Arechavala‐Gomeza, V., Ricotti, V., Torelli, S., Feng, L., Janghra, N., Tasca, G. A., Guglieri, M., Barresi, R., Armaroli, A., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4908 · Cited by 105
Li, C., Diprimio, N., Bowles, D. E., Hirsch, M. L., Monahan, P. E., Asokan, A., Rabinowitz, J., Agbandje-McKenna, M., & Samulski, R. J. (2012) · Journal of Virology · doi:10.1128/jvi.00675-12 · Cited by 96
“A number of surveys have demonstrated that NAb cross-activity exists among types of AAV (6, 10, 27, 45).”
BackgroundSelf-citationHerson, S., Hentati, F., Rigolet, A., Behin, A., Romero, N. B., Leturcq, F., Laforêt, P., Maisonobe, T., Amouri, R., Haddad, H., et al. (2012) · Brain · doi:10.1093/brain/awr342 · Cited by 91
“This difference may be due to the use of a higher injected dose, but it should also be noted that at baseline, patients had detectable -SGC staining by immunohistochemistry or western blot (Mendell et al., 2009, 2010).”
BackgroundInfluentialArechavala-Gomeza, V., Anthony, K., Morgan, J., & Muntoni, F. (2012) · Current Gene Therapy · doi:10.2174/156652312800840621 · Cited by 94
“both against revertant and novel dystrophin epitopes remains a possibility (94) and presents a new issue to address”
BackgroundShimizu-Motohashi, Y., Komaki, H., Motohashi, N., Takeda, S., Yokota, T., & Aoki, Y. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010001 · Cited by 82
“However, in patients with no detectable micro-dystrophin, two had elevated T cell responses to dystrophin epitopes from endogenous and/or transgene products after vector delivery, indicative of transgene expression even when the functional protein was undetectable [49,50], and a third patient exhibited T cell response…”
BackgroundMethodMuscle Wasting Diseases: Novel Targets and Treatments
Furrer, R., & Handschin, C. (2018) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021041 · Cited by 103
“Based on these promising pre-clinical data, several phase I/II clinical trials are currently being planned or conducted aiming at treating DMD patients with mini- or micro-dystrophin (see Table 1) (100).”
BackgroundAdeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 97
“The prevalence of NAbs in children is lower, ranging from 13 to 25% (216, 219).”
BackgroundSelf-citationMendell, J. R., Shieh, P. B., McDonald, C. M., Sahenk, Z., Lehman, K. J., Lowes, L. P., Reash, N. F., Iammarino, M. A., Alfano, L. N., Sabo, B., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1167762 · Cited by 93
“Eligibility criteria included: ≥4 to <8 years of age at the time of screening in Part 1; a confirmed mutation in the DMD gene (frameshift [deletion or duplication] or premature stop codon mutation) between exons 18 and 58 to limit potential immune responses to the transgene (Mendell et al., 2010); creatine kinase >1,0…”
BackgroundSelf-citationClinical development on the frontier: gene therapy for duchenne muscular dystrophy
Asher, D. R., Thapa, K., Dharia, S. D., Khan, N., Potter, R. A., Rodino‐Klapac, L. R., & Mendell, J. R. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1725469 · Cited by 99
Self-citationGene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock
Martier, R., & Konstantinova, P. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580179 · Cited by 100
Malik, V., Rodino‐Klapac, L. R., Viollet, L., & Mendell, J. R. (2010) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285610388693 · Cited by 103
“The overall issue has relevance to other treatment modalities expressing novel dystrophin epitopes including gene therapy and exon skipping [Mendell et al. 2010].”
BackgroundSelf-citationAnthony, K., Arechavala‐Gomeza, V., Taylor, L. E., Vulin, A., Kaminoh, Y., Torelli, S., Feng, L., Janghra, N., Bonne, G., Beuvin, M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001025 · Cited by 89
Linker proteins restore basement membrane and correct LAMA2 -related muscular dystrophy in mice
Reinhard, J. R., Lin, S., McKee, K. K., Meinen, S., Crosson, S. C., Sury, M., Hobbs, S., Maier, G., Yurchenco, P. D., & Rüegg, M. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4649 · Cited by 93
T Cell-Mediated Immune Responses to AAV and AAV Vectors
Ertl, H. C. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666666 · Cited by 88
Zhang, P., Sun, B., Osada, T., Rodriguiz, R., Yang, X. Y., Luo, X., Kemper, A. R., Clay, T. M., & Koeberl, D. D. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.063 · Cited by 88
“The clinical relevance of transgene-directed immune responses has been emphasized in a clinical trial in subjects with Duchenne muscular dystrophy, although CTLs in that trial appeared to be related to previous T cell activation that might be resistant to immunomodulatory gene therapy (Mendell et al., 2010).”
Xu, L., Lu, P., Wang, C., Keramaris, E., Qiao, C., Xiao, B., Blake, D. J., Xiao, X., & Lu, Q. L. (2013) · Molecular Therapy · doi:10.1038/mt.2013.156 · Cited by 96
Self-citationShimizu‐Motohashi, Y., Miyatake, S., Komaki, H., Takeda, S., & Aoki, Y. (2016) · Europe PMC (PubMed Central) · Cited by 101
Taniguchi‐Ikeda, M., Morioka, I., Iijima, K., & Toda, T. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.07.003 · Cited by 91
“…gene therapies have been intensively investigated in the past decade with respect to the treatment of a variety of genetic diseases and clinical trials for DMD by administeringminidystrophin with AAV have been initiated (Bowles et al., 2012; Mendell et al., 2010; Rodino-Klapac et al., 2010).”
BackgroundAAV Genome Loss From Dystrophic Mouse Muscles During AAV-U7 snRNA-mediated Exon-skipping Therapy
Le Hir, M., Goyenvalle, A., Peccate, C., Précigout, G., Davies, K. E., Voit, T., Garcia, L., & Lorain, S. (2013) · Molecular Therapy · doi:10.1038/mt.2013.121 · Cited by 80
Gene therapy for haemophilia: a long and winding road
High, K. A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04369.x · Cited by 86
Koo, T., Lu‐Nguyen, N., Malerba, A., Kim, E., Kim, D., Cappellari, O., Cho, H., Dickson, G., Popplewell, L. J., & Kim, J. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.018 · Cited by 90
Stem cell therapy for muscular dystrophies
Biressi, S., Filareto, A., & Rando, T. A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci142031 · Cited by 88
Potter, R. A., Griffin, D. A., Heller, K. N., Peterson, E. L., Clark, E. K., Mendell, J. R., & Rodino‐Klapac, L. R. (2021) · Human Gene Therapy · doi:10.1089/hum.2019.255 · Cited by 89
Self-citationGene and cell‐mediated therapies for muscular dystrophy
Konieczny, P., Swiderski, K., & Chamberlain, J. S. (2012) · Muscle & Nerve · doi:10.1002/mus.23738 · Cited by 95
“Furthermore, it has become evident that DMD patients, who generally have an almost complete lack of dystrophin protein, may mount an immune response to the therapeutic gene, especially in patients who carry deletions.(24) To overcome this concern, several groups are now investigating the potential of delivering utroph…”
BackgroundMuscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future
Łoboda, A., & Dulak, J. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00134-x · Cited by 94
The immune system in Duchenne muscular dystrophy: Friend or foe
Villalta, S. A., Rosenberg, A. S., & Bluestone, J. A. (2015) · Rare Diseases · doi:10.1080/21675511.2015.1010966 · Cited by 83
“Although the evidence is circumstantial and anecdotal, the findings of a recent dystrophin gene therapy trial corroborate the concern that pre-existing dystrophin-reactive T cells may limit the clinical efficacy of gene therapy.(52) Moreover, recent studies showing that Treg identity and function may become destabiliz…”
ResultLiver induced transgene tolerance with AAV vectors
Keeler, G. D., Markusic, D. M., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.002 · Cited by 81
Prasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy
Bertolini, T. B., Shirley, J. L., Zolotukhin, I., Li, X., Kaisho, T., Xiao, W., Kumar, S. R. P., & Herzog, R. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672449 · Cited by 80
“Interestingly, pre-existing cellular immunity to dystrophin may occur in some patients with Duchene’s muscular dystrophy, a disease characterized by muscle regeneration and some level inflammation (55).”
BackgroundChowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 82
Advances in genetic therapeutic strategies for Duchenne muscular dystrophy
Guiraud, S., Chen, H., Burns, D. T., & Davies, K. E. (2015) · Experimental Physiology · doi:10.1113/ep085308 · Cited by 81
“While transgene expression was undetectable, a T-cell-specific immune response to mini-dystrophin was encountered in these patients (Mendell et al. 2010).”
BackgroundTherapeutic advances in muscular dystrophy
Leung, D. G., & Wagner, K. R. (2013) · Annals of Neurology · doi:10.1002/ana.23989 · Cited by 84
“An important finding from a recent gene therapy trial (using AAV vectors carrying mini-dystrophin) was that an immune reaction to dystrophin occurred in some patients.(64,96,97) Two of 6 subjects had dystrophin-specific T-cell responses prior to treatment consistent with priming, perhaps by rare revertant myofibers ex…”
BackgroundDuchenne Muscular Dystrophy Gene Therapy in the Canine Model
Duan, D. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.006 · Cited by 88
“But nominal transduction is detected in DMD patients following direct injection.(43) Similar to human patients, intramuscular injection also induces robust immune rejection in affected dogs (Table 2).”
Wang, Z., Storb, R. F., Halbert, C. L., Banks, G. B., Butts, T. M., Finn, E. E., Allen, J. M., Miller, A. D., Chamberlain, J. S., & Tapscott, S. J. (2012) · Molecular Therapy · doi:10.1038/mt.2012.111 · Cited by 81
Askanas, V., & Engel, W. K. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2010.11.024 · Cited by 80
“Interestingly, in muscle biopsies of some patients with Duchenne muscular dystrophy caused by dystrophin mutation there is T-cell-inflammation, which has now been shown to be elicited by revertant dystrophin or mini-dystrophin therapeutically delivered by an rAAV vector, both of which apparently are not recognized as…”
Colella, P., Sellier, P., Costa Verdera, H., Puzzo, F., van Wittenberghe, L., Guerchet, N., Daniele, N., Gjata, B., Marmier, S., Charles, S., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.002 · Cited by 74
“This finding is particularly relevant for gene delivery to muscle, a tissue reported to be highly proimmunogenic.(9,26,32,36,76,77)”
BackgroundGrose, W. E., Clark, K. R., Griffin, D., Malik, V., Shontz, K. M., Montgomery, C. L., Lewis, S., Brown, R. H., Janssen, P. M. L., Mendell, J. R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039233 · Cited by 76
“Although mini-genes are desirable for practicality of standard AAV delivery, there is a compromise in protein function [28] and the potential for novel epitopes that may be immunogenic when delivered to patients [41].”
BackgroundMethodSelf-citationFlanigan, K. M. (2012) · Seminars in Neurology · doi:10.1055/s-0032-1329199 · Cited by 90
Duchenne muscular dystrophy: current cell therapies
Sienkiewicz, D., Kułąk, W., Okurowska-Zawada, B., Paszko-Patej, G., & Kawnik, K. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615586123 · Cited by 89
Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy
Fortunato, F., Rossi, R., Falzarano, M. S., & Ferlini, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040820 · Cited by 64
“Treated patients failed to express the synthetic minidystrophin; on the contrary, the specific T cell cluster against mini-dystrophin was detected even when the protein was not expressed [77].”
BackgroundVieira, N. M., Valadares, M. C., Zucconi, E., Secco, M., Júnior, C. R. B., Brandalise, V., Assoni, A. F., Gomes, J., Landini, V., Andrade, T., et al. (2011) · Cell Transplantation · doi:10.3727/096368911x · Cited by 77
Chicoine, L. G., Rodino‐Klapac, L. R., Shao, G., Xu, R., Bremer, W. G., Camboni, M., Golden, B., Montgomery, C. L., Shontz, K. M., Heller, K. N., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.246 · Cited by 80
Self-citationLong‐term functional adeno‐associated virus‐microdystrophin expression in the dystrophic CXMDj dog
Koo, T., Okada, T., Athanasopoulos, T., Foster, H., Takeda, S., & Dickson, G. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1602 · Cited by 74
“Importantly, of the six treated patients, two subjects appeared to exhibit preexisting dystrophin specific T-cells, possibly reacting against rare dystrophin-positive revertant fibers, in peripheral blood mononuclear cells before treatment [18].”
BackgroundMethodInfluentialVidović, D., Carlon, M. S., da Cunha, M. F., Dekkers, J. F., Hollenhorst, M. I., Bijvelds, M. J. C., Ramalho, A. S., Van den Haute, C., Ferrante, M., Baekelandt, V., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-0914oc · Cited by 74
Therapeutic promise of engineered nonsense suppressor tRNAs
Porter, J. J., Heil, C. S., & Lueck, J. D. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1641 · Cited by 77
Current Translational Research and Murine Models For Duchenne Muscular Dystrophy
Rodrigues, M., Echigoya, Y., Fukada, S., & Yokota, T. (2016) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-150113 · Cited by 79
Majowicz, A., Salas, D., Zabaleta, N., Rodríguez‐García, E., González‐Aseguinolaza, G., Petry, H., & Ferreira, V. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.003 · Cited by 76
“However, the immune responses against the transgene proteins do not occur systematically in all of the animals, and the generation of immune responses against transgene products has been suggested in clinical trials.(34,35) Therefore, the immune mechanisms occurring in NHPs might be relevant as a model to develop stra…”
Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy
Robinson-Hamm, J. N., & Gersbach, C. A. (2016) · Human Genetics · doi:10.1007/s00439-016-1725-z · Cited by 82
“However, there were very few dystrophin-positive fibers in only some patients even though the viral genomes were easily detectable in muscle biopsies (Mendell et al. 2010).”
BackgroundResultAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
“However, underlying mutations (92), even single-amino acid substitutions or transgene-derived cryptic epitopes (84, 93) can induce transgene product-specific cellular responses restricted to tissue-resident T-cells (109).”
BackgroundInfluentialManini, A., Abati, E., Nuredini, A., Corti, S. P., & Comi, G. P. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.814174 · Cited by 82
“2/6 at 42 days Completed NCT00428935 (98, 99)”
BackgroundMethodResultInfluentialMajowicz, A., Maczuga, P., Kwikkers, K. L., van der Marel, S., van Logtenstein, R., Petry, H., van Deventer, S. J. H., Konstantinova, P. S., & Ferreira, V. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2712 · Cited by 78
“However, immune suppression protocols have not always proven to be effective [29], as observed in a clinical study where AAV-based gene therapy was used in patients with Duchenne’s muscular dystrophy [27].”
BackgroundMethodResultGenome engineering: a new approach to gene therapy for neuromuscular disorders
Nelson, C. E., Robinson-Hamm, J. N., & Gersbach, C. A. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.126 · Cited by 76
Progress and prospects of gene therapy clinical trials for the muscular dystrophies
Bengtsson, N. E., Seto, J. T., Hall, J. K., Chamberlain, J. S., & Odom, G. L. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv420 · Cited by 76
“5 vector used, evidence of a T-cell immune response against some dystrophin epitopes was found in both injected and non-injected patients (53,54).”
BackgroundResultImmunological barriers to haematopoietic stem cell gene therapy
Charlesworth, C. T., Hsu, I., Wilkinson, A. C., & Nakauchi, H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00698-0 · Cited by 74
Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy
Govoni, A., Magri, F., Brajkovic, S., Zanetta, C., Faravelli, I., Corti, S. P., Bresolin, N., & Comi, G. P. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1396-z · Cited by 71
Gupta, S., Richards, S. M., Amaravadi, L. S., Piccoli, S. P., Desilva, B. S., Pillutla, R. C., Stevenson, L. F., Mehta, D. S., Carrasco‐Triguero, M., Neely, R. J., et al. (2017) · Bioanalysis · doi:10.4155/bio-2017-4974 · Cited by 75
Kiourtis, C., Wilczynska, A., Nixon, C., Clark, W. A., May, S., & Bird, T. G. (2021) · Biology Open · doi:10.1242/bio.058678 · Cited by 74
“Even though in humans evidence suggests that the immune system might compromise AAV8 efficiency (partly due to cross-immunity with adenoviruses) there have not been detailed studies on the murine immune response against AAV8 (Boutin et al., 2010; Mendell et al., 2010; Calcedo et al., 2011).”
BackgroundNew developments in the use of gene therapy to treat Duchenne muscular dystrophy
Jarmin, S., Kymäläinen, H., Popplewell, L. J., & Dickson, G. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.866087 · Cited by 75
“This highlights the importance not only of the selection of rAAV but also the promoter within the vector [98,119].”
BackgroundBirch, S. M., Lawlor, M. W., Conlon, T. J., Guo, L., Crudele, J. M., Hawkins, E. C., Nghiem, P. P., Ahn, M., Meng, H., Beatka, M. J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo1815 · Cited by 70
López-Gordo, E., Chamberlain, K., Riyad, J. M., Kohlbrenner, E., & Weber, T. (2024) · Viruses · doi:10.3390/v16030442 · Cited by 70
“5 [290] has been tested for the delivery of mini-dystrophin for Duchenne muscular dystrophy ([218,290], NCT00428935 [200]); rAAV-Oligo001 [373] has been used for Typical Canavan Disease in children (NCT04833907 [200]); 4D-R100 has been trialed for Choroideremia or retinitis pigmentosa (NCT04483440…”
MethodCardiac and Respiratory Dysfunction in Duchenne Muscular Dystrophy and the Role of Second Messengers
Mosqueira, M., Zeiger, U., Förderer, M., Brinkmeier, H., & Fink, R. (2013) · Medicinal Research Reviews · doi:10.1002/med.21279 · Cited by 72
Goyenvalle, A., Wright, J., Babbs, A., Wilkins, V., García, L., & Davies, K. E. (2012) · Molecular Therapy · doi:10.1038/mt.2012.26 · Cited by 66
Assessment of Humoral, Innate, and T-Cell Immune Responses to Adeno-Associated Virus Vectors
Calcedo, R., Chichester, J. A., & Wilson, J. M. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.038 · Cited by 67
Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?
Wagner, D. L., Peter, L., & Schmueck-Henneresse, M. (2021) · Gene Therapy · doi:10.1038/s41434-021-00232-2 · Cited by 63
The Immune System in Duchenne Muscular Dystrophy Pathogenesis
Tripodi, L., Villa, C., Molinaro, D., Torrente, Y., & Farini, A. (2021) · Biomedicines · doi:10.3390/biomedicines9101447 · Cited by 73
“2 sub-population of T-lymphocytes that over-expressed the osteopontin that modulates the activity of neutrophils and Tregs, mediating the development of fibrosis [65].”
BackgroundProgress in therapy for Duchenne muscular dystrophy
Fairclough, R. J., Bareja, A., & Davies, K. E. (2011) · Experimental Physiology · doi:10.1113/expphysiol.2010.053025 · Cited by 74
“However, a recent clinical trial using intramuscular injections of AAV2 into DMD patients did not result in good restoration of dystrophin expression and highlighted the potential for T cell immunity to dystrophin epitopes (Mendell et al. 2010).”
ResultLek, A., Atas, E., Hesterlee, S. E., Byrne, B. J., & Bönnemann, C. G. (2023) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-221639 · Cited by 65
“[26] which described detection of dystrophin-specific T cells in a subset of DMD patients both pre- and post- gene therapy.”
BackgroundUpdate on the Treatment of Duchenne Muscular Dystrophy
Rodino‐Klapac, L. R., Mendell, J. R., & Sahenk, Z. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0332-1 · Cited by 69
“There are a growing number of therapeutic strategies based on the concept of upregulating or overexpressing alternative genes to compensate for the loss of dystrophin [9].”
Self-citationDuchenne muscular dystrophy: CRISPR/Cas9 treatment
Mendell, J. R., & Rodino‐Klapac, L. R. (2016) · Cell Research · doi:10.1038/cr.2016.28 · Cited by 62
Self-citationThe progress of AAV-mediated gene therapy in neuromuscular disorders
Aguti, S., Malerba, A., & Zhou, H. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1479739 · Cited by 67
“Although this response was at least partially triggered by using a CMV promoter and a chimeric engineered capsid, this study pointed out the necessity of prescreening patients for related antibodies, before admission into trials, since the failure to maintain long-term transgene expression is secondary to the immune r…”
BackgroundAAV for Gene Therapy in Ocular Diseases: Progress and Prospects
He, X., Fu, Y., Ma, L., Yao, Y., Ge, S., Yang, Z. H., & Fan, X. (2023) · Research · doi:10.34133/research.0291 · Cited by 79
“5, AAV2tYF, and AAV.7m8, have been applied in clinical trials for various types of diseases [54–56].”
MethodGene therapy for Duchenne muscular dystrophy
Ramos, J. N., & Chamberlain, J. S. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1088780 · Cited by 69
“AAV capsid and transgene-specific responses by effector CD8 cells has been reported in multiple animal models and in humans [37,38,79-86].”
BackgroundMethodInfluentialDuchenne muscular dystrophy gene therapy: Lost in translation?
Duan, D. (2011) · Research and Reports in Biology · doi:10.2147/rrb.s13463 · Cited by 68
“AAV vector.(113) This result was totally unpredicted by the mouse studies.”
BackgroundResultFuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61
Complexity of immune responses to AAV transgene products – Example of factor IX
Herzog, R. W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.05.006 · Cited by 60
“Thus far, such responses have been rare in clinical trials (although, cases of CD8+ T cell responses against dystrophin and α1-antitrypsin have been documented upon intramuscular administration of AAV vectors) [5, 6].”
BackgroundWasala, N. B., Yue, Y., Lostal, W., Wasala, L. P., Niranjan, N., Hajjar, R. J., Babu, G. J., & Duan, D. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.011 · Cited by 63
“For example, newly restored dystrophin could be recognized as a new antigen by the immune system and induce an immune reaction.(21) Mutation-targeted exon-skipping and genomic-editing approaches have to be individually tailored to the mutation.”
BackgroundImmunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
“Moreover, transgene protein product-specific CTL was observed in human rAAV trials for Duchenne’s Muscular Dystrophy (14) and a-1-antitrypsin (15).”
BackgroundQuantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens
Taylor, L. E., Kaminoh, Y., Rodesch, C. K., & Flanigan, K. M. (2012) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01250.x · Cited by 59
Cheng, B., Ling, C., Dai, Y., Lu, Y., Glushakova, L. G., Gee, S. W. Y., McGoogan, K. E., Aslanidi, G. V., Park, M., Stacpoole, P. W., et al. (2012) · Gene Therapy · doi:10.1038/gt.2011.105 · Cited by 59
Structure-function relationships of nonviral gene vectors: Lessons from antimicrobial polymers
Xing, H., Lu, M., Yang, T., Liu, H., Sun, Y., Zhao, X., Xu, H., Yang, L., & Ding, P. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.12.041 · Cited by 60
Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies
Soblechero‐Martín, P., López‐Martínez, A., Ovejero, L. D. L. P., Vallejo‐Illarramendi, A., & Arechavala‐Gomeza, V. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12735 · Cited by 65
“Developing gene therapy treatments for Duchene muscular dystrophy is challenging for three main reasons: first, both full- length DMD or UTRN genes, and even their cDNAs, are too large and need to be engineered into truncated (‘mini’ or ‘micro’) constructs in order to be packaged into adeno- associated virus (AAV), wh…”
BackgroundNitahara‐Kasahara, Y., Hayashita‐Kinoh, H., Ohshima-Hosoyama, S., Okada, H., Wada-Maeda, M., Nakamura, A., Okada, T., & Takeda, S. (2011) · Molecular Therapy · doi:10.1038/mt.2011.181 · Cited by 63
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies
Benedetti, S., Hoshiya, H., & Tedesco, F. S. (2013) · FEBS Journal · doi:10.1111/febs.12178 · Cited by 66
Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy
Abreu, N. J., & Waldrop, M. A. (2020) · Pediatric Pulmonology · doi:10.1002/ppul.25055 · Cited by 61
“Safety was established, but transfer resulted in no significant levels of microdystrophin expression.(96) In addition, evidence of immunogenicity was noted with detectable T‐cell responses to the AAV vector and the microdystrophin transgene.”
BackgroundMarrone, L., Marchi, P. M., & Azzouz, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2012148 · Cited by 56
Wang, Z., Tapscott, S. J., Chamberlain, J. S., & Storb, R. F. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00201 · Cited by 64
“A recent phase I trial on DMD from Mendell et al. (2010a) also raised the potential of cellular immune responses to either self or non-self dystrophin epitopes.”
BackgroundInfluentialGene therapy for cystic fibrosis: Challenges and prospects
Sui, H., Xu, X., Su, Y., Gong, Z., Yao, M., Liu, X., Zhang, T., Jiang, Z., Bai, T., Wang, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1015926 · Cited by 60
“Transgene protein product-specific CTL was also observed in rAAV trials for Duchenne’s Muscular Dystrophy (Mendell et al., 2010) and α1-antitrypsin (Calcedo et al., 2017).”
BackgroundPKC Theta Ablation Improves Healing in a Mouse Model of Muscular Dystrophy
Madaro, L., Pelle, A., Nicoletti, C., Crupi, A. N., Marrocco, V., Bossi, G., Soddu, S., & Bouché, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031515 · Cited by 54
Boisgerault, F., & Mingozzi, F. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630121750 · Cited by 54
Progress and challenges of gene therapy for Pompe disease
Ronzitti, G., Collaud, F., Laforêt, P., & Mingozzi, F. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.67 · Cited by 56
“While intramuscular administration of AAV vectors allows to achieve highly efficient tissue transduction, concerns over transgene immunogenicity (98,99), and the systemic nature of the disease, make this route of vector delivery unsuitable to treat effectively PD.”
BackgroundXiao, Y., Muhuri, M., Li, S., Qin, W., Xu, G., Luo, L., Li, J., Letizia, A. J., Wang, S. K., Chan, Y. K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.99052 · Cited by 53
Self-citationStem Cell Transplantation for Muscular Dystrophy: The Challenge of Immune Response
Maffioletti, S. M., Noviello, M., English, K., & Tedesco, F. S. (2014) · BioMed Research International · doi:10.1155/2014/964010 · Cited by 60
“[111] J.”
BackgroundHumoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
“In the clinic however, anti-transgene cellular immune responses have only been observed in rare cases, usually in trials utilising the intramuscular delivery route, such as anti-Dystrophin T-cells in Duchenne’s Muscular Dystrophy (DMD) trials, for example (Mendell et al., 2010).”
Nance, M. E., & Duan, D. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.107 · Cited by 57
Metadata
- Authors
- Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., Malik, V., Coley, B., Clark, K. R., Li, J., Xiao, X., Samulski, J., McPhee, S. W., Samulski, R. J., & Walker, C. M.
- Affiliations
- Nationwide Children's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- AskBio (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-10-07
- Volume
- 363
- Issue
- 15
- Pages
- 1429-1437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3014106
- OpenAlex
- W2116885047
- Cited by
- 655
- References
- 25
- Citations by year
- 2026: 21 · 2025: 22 · 2024: 38 · 2023: 44 · 2022: 49 · 2021: 42 · 2020: 44 · 2019: 47 · 2018: 31 · 2017: 42 · 2016: 28 · 2015: 47 · 2014: 34 · 2013: 54 · 2012: 60
- FWCI
- 21.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI060388)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- Duchenne muscular dystrophy, dystrophin, autoreactive T cells, T cell immunity, dystrophin gene deletion
- MeSH terms
- Dependovirus, Autoantibodies, Child, DNA, Viral, Genetic Vectors, Humans, Immunity, Cellular, Male, T-Lymphocytes, Protein Biosynthesis, Genetic Therapy, Autoimmunity, Dystrophin, Frameshift Mutation, Muscle, Skeletal, Transgenes, Muscular Dystrophy, Duchenne
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.